13F Pro13F Pro

Foresite Capital Management VI LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2013341
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare96.7%$621.1M
  • Technology2.9%$18.3M
  • Financials0.5%$3.2M

AUM History

13fpro.ai/research/fund/foresite-capital-management-vi-llc-2013341

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/foresite-capital-management-vi-llc-2013341

Foresite Capital Management VI LLC 13F holdings — Q2 2026

$642.6M portfolio (+39.6% QoQ) · 23 holdings · Q2 2026 13F · top 10 are 82% of the stock portfolio

All holdings — Foresite Capital Management VI LLC (Q2 2026)

23 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
HNGE$HNGEHinge Health, Inc.$18.3M—
KYMR$KYMRKymera Therapeutics, Inc.$16.8M—
ATAI.R1840904$ATAI.R1840904Atai Beckley N.V.$14.5M—
VSTM$VSTMVerastem, Inc.$12.0M—
BEAM$BEAMBeam Therapeutics Inc.$11.3MNew
NERV$NERVMinerva Neurosciences, Inc.$11.0M-0.1%
AVBP$AVBPArriVent BioPharma, Inc.$10.5MNew
AURA$AURAAura Biosciences, Inc.$9.5MNew
CRNX$CRNXCrinetics Pharmaceuticals, Inc.$7.9M—
RACC$RACCResearch Alliance Corp III$3.2MNew
ZURA$ZURAZura Bio Ltd$2.7M—
KLRA$KLRAKailera Therapeutics, Inc.$826KNew
IRON$IRONDisc Medicine, Inc.$71KNew

What changed in Q2 2026

Against the previous quarter's 13F: 8 new, 6 added to, 1 trimmed, 2 sold out. Share-count changes; largest moves by dollar size first.

New positions (8)

  • SPTX$SPTXSeaport Therapeutics, Inc.$38.7M

    first bought this quarter

  • PBLS$PBLSParabilis Medicines, Inc.$27.3M

    first bought this quarter

  • BEAM$BEAMBeam Therapeutics Inc.$11.3M

    first bought this quarter

  • AVBP$AVBPArriVent BioPharma, Inc.$10.5M

    first bought this quarter

  • AURA$AURAAura Biosciences, Inc.$9.5M

    first bought this quarter

  • RACC$RACCResearch Alliance Corp III$3.2M

    first bought this quarter

+2 more in the Excel export

Added to (6)

  • CLDX$CLDXCelldex Therapeutics, Inc.+178%

    now $32.7M · held 2 qtrs, 2 adds in a row

  • GHRS$GHRSGH Research PLC+198%

    now $25.3M · held 2 qtrs, 2 adds in a row

  • JBIO$JBIOJade Biosciences, Inc.+177%

    now $19.7M · held 2 qtrs, 2 adds in a row

  • CGON$CGONCG Oncology, Inc.+7%

    now $168.4M · held 7+ qtrs

  • AGIO$AGIOAGIOS PHARMACEUTICALS, INC.+50%

    now $29.1M · held 3 qtrs

  • DNLI$DNLIDenali Therapeutics Inc.+15%

    now $35.9M · held 4 qtrs, 2 adds in a row

Trimmed (1)

  • NERV$NERVMinerva Neurosciences, Inc.-0.1%

    now $11.0M · held 2 qtrs

Sold out (2)

  • CNTA$CNTACentessa Pharmaceuticals plcwas $54.2M

    held 6+ qtrs

  • OKUR$OKUROnKure Therapeutics, Inc.was $6.0M

    held 1 qtr

Holdings by quarter

Every 13F Foresite Capital Management VI LLC has filed, 6 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Foresite Capital Management VI?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Foresite Capital Management VI's top 20 holdings: 21/100 (our AI quality score, weighted by position size; 9 of the 20 are scored)

Top 10 since filing

-33.2%

Value-weighted move of the 10 largest stock positions

Turnover

11%

Last quarter; 45% over the last 4

Top 10 weight

82%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

62%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Foresite Capital Management VI LLC disclosed 23 positions worth $642.6M in its Form 13F-HR for Q2 2026, led by $CGON (CG Oncology, Inc.) at 26.2% of the equity portfolio, followed by $ALMS and $SPTX. During the quarter the fund opened 8 new positions and exited 2 — including a new stake in $SPTX and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (96.7% of disclosed assets). All figures are sourced directly from Foresite Capital Management VI LLC’s Form 13F-HR filing with the SEC under CIK 2013341.

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Foresite Capital Management VI LLC

13F Pro is an AI hedge fund tracker and stock research platform. For Foresite Capital Management VI LLC (SEC CIK: 2013341), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Foresite Capital Management VI LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.